Novel formulation and clinical evaluation of nalidixic acid ointment in impetigo

The aim of this work was to formulate and evaluate nalidixic acid for the first time in different topical ointment bases. Among different ointment formulations, hydrocarbon base achieved the lowest release, while water-soluble base achieved the highest release. The presence of both isopropanol as co...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2012, Vol.22 (4), p.347-352
Main Authors: Tous, S.S., El Sayed, A.M., Abd El Mohsen, M.G., Youssef, E.M.K., Agban, M.N., Boushra, M.F.
Format: Article
Language:English
Subjects:
Antibacterial activity
Benzoic acid
Biological and medical sciences
Drug delivery
General pharmacology
Hydrocarbons
Impetigo
Medical sciences
Nalidixic acid
Ointment
Ointments
pH effects
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Release
Stability
Therapeutic applications
Thin-layer chromatography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this work was to formulate and evaluate nalidixic acid for the first time in different topical ointment bases. Among different ointment formulations, hydrocarbon base achieved the lowest release, while water-soluble base achieved the highest release. The presence of both isopropanol as cosolvent and nalidixic acid-sodium benzoate solid dispersion in formula (W8) enhanced both the release and the antibacterial activity of nalidixic acid compared to ointment formula (W5) containing neither of them. A stability study was also performed where no significant change in pH or drug content was observed in all stored formulations (W5 and W8). Stability was further checked by thin-layer chromatography (TLC). After clinical application in impetigo, it was found that the presence of isopropanol and nalidixic acid-sodium benzoate solid dispersion in ointment formulation (W8 ) caused a significant reduction in the mean time of healing (only four days) in impetigo patients.
ISSN:1773-2247
DOI:10.1016/S1773-2247(12)50058-4